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Abstract
Background: Metastasis to the seminal vesicle is extremely rare for hepatocellular carcinoma (HCC). To our
knowledge, it has been not reported in literature. The purpose of the present paper was to report a case of
metastasis to the seminal vesicle after HCC resection, along with its histological features and immunohistochemical
characteristics.
Case Presentation: A 46-year-old Chinese man was admitted to our hospital due to abdominal distension. He had a
history of HCC related to hepatitis B virus infection. Moreover, left partial hepatectomy was performed in another
hospital 28 months ago, and right partial hepatectomy for HCC recurrence in our hospital 4 months ago. After
resection, radiofrequency ablation therapy had been performed. About 27 months after the initial operation, contrast-
enhanced computed tomography (CT) of the pelvic cavity revealed a mass with homogeneous enhancement in the
seminal vesicle. Transrectal needle biopsy revealed a poorly differentiated adenocarcinoma. Therefore, seminal
vesiculectomy was resected. The histological diagnosis of the removed tumor was compatible with the original HCC.
Immunohistochemical examination demonstrated that the tumor cells were positive for glypican-3 (GPC3), alpha-
fetoprotein (AFP), hepatocyte paraffin-1 (Hep Par 1), cytokeratin 18 (CK 18), and hepatocyte antigen, which confirmed
that the seminal vesicle tumor was a metastatic tumor of HCC. However, CT subsequently revealed multiple metastatic
foci in the abdominal and pelvic cavities in May 2009 and August 2009, respectively.
Conclusion: The seminal vesicle is an extremely rare metastatic site for HCC, and the prognosis is very poor. A
combination of clinical and pathological features is necessary for a correct diagnosis, and primary tumor should be
excluded before diagnosing metastatic foci.
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Background
Hepatocellular carcinoma (HCC) is one of the most
common malignancies worldwide, accounting for nearly
one million new cases each year [1]. The long-term
prognosis for HCC remains poor, with a 5-year survival
rate of < 5% [2], and intrahepatic and extrahepatic
metastasis are the most important factors. The liver is
the most common site of HCC metastasis, accounting
for approximately 85% to 90% of all cases [3]. Extrahe-
patic metastases have been reported to occur in 13.5%
to 42% of HCC patients [4-6]. The most frequent sites
of extrahepatic metastases are lung, abdominal lymph
node, and bone [4,7,8]. To our knowledge, it has not
been reported in literature that HCC metastasize to the
seminal vesicle. Here we report the case of a 46-year-old
man with metastatic HCC to the seminal vesicle after a
liver resection for HCC and recurrence, and observed its
histological and immunohistochemical characteristics.
Case presentation
A 46-year-old Chinese man was admitted to our hospi-
tal due to abdominal distension in January 2009. It was
the second time that he was as an inpatient of our
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approximately ten years. Moreover, his mother, two
older brothers, and older sister had histories of hepatitis
B. Among them, one older brother died from HCC
three years ago. He began to notice his weight loss since
June 2006, and performed a health examination in local
hospital in August 2006. Laboratory test results included
the following: white blood cell count, 4800/μl; hemoglo-
bin, 10.3 g/dl; platelets, 84 × 10
3/μl; aspartate amino-
transferase, 42 U/L; alanine aminotransferase, 30 U/L
(Table 1). Hepatitis B surface antigen, hepatitis B e anti-
gen, and hepatitis B core anti b o d yw e r ep o s i t i v e .T h e
level of serum alpha-fetoprotein (AFP) was elevated to
3350 ng/ml (normal level < 20 ng/ml), whereas serum
carcinoembryonic antigen (CEA) and human chorionic
gonadotropin (HCG) levels were within normal limits.
Abdominal ultrasound examination revealed a solitary
mass, which was determined to be HCC by liver needle
biopsy. Sequentially, the patient underwent partial resec-
tion of the left anterior segment of the liver (about 2 cm
in diameter) in local hospital in September 2006. After
leaving the hospital, the patient received thymic peptide
injections twice a week, but the dosage was not pro-
vided. About half a year after the initial operation,
abdominal ultrasound examination revealed a mass in
the right lobe of the liver, which was determined to be
recurrent HCC (Figure 1). Thus, regular (one time/three
months) radiofrequency ablation therapy (60W, 2 min/
time; the total 3 times) and transarterial interventions
(embolization or chemoembolization) were performed
until September 2008. During therapy, the serum level
of AFP was elevated (21.51-4689 ng/ml) (the details
could be seen in table 1). However, abdominal ultra-
sound examination also revealed multiple solid occupa-
tion in the liver (Figure 2 and 3). Thus, the patient
underwent partial resection of the right anterior seg-
ment for HCC recurrence in our hospital on September
20, 2008. After operation, the patient was not received
any antitumoral therapy due to his weakness. On
December 23, 2008, he went to see a doctor for abdom-
inal distension in local hospital. Contrast-enhanced
computed tomography (CT) of the pelvic cavity revealed
a mass (5.0 cm in diameter) with homogeneous
enhancement in the seminal vesicle. Transrectal needle
biopsy revealed a poorly differentiated adenocarcinoma
with histological characteristic similar to that of the ori-
ginal HCC. Considering the patient’s history, the doctors
diagnosed the mass in the seminal vesicle as a meta-
static focus. Unfortunately, the CT image and biopsy
were not obtained from the other hospital. In order to
receive further treatment, he came to our hospital. Dur-
ing the operation, only a mass with the size of 4.8 cm in
diameter was found in left seminal vesicle, but involved
right seminal vesicle. Thus, bilateral seminal vesicle and
prostate were resected. Macroscopically, the structure of
the seminal vesicle was unclear and replaced by tumor
tissues with hemorrhage. Histologically, the removed
tumor was found to be compatible with the original
HCC. Tumor cells arranged in trabecular, solid, or tubu-
lar patterns. Nuclei and nucleoli were prominent, and
the cytoplasm was scanty and basophilic (Figure 4).
Moreover, immunohistochemical examination demon-
strated that the tumor cells were positive for glypican-3
(GPC3) (Figure 5), AFP (Figure 6), hepatocyte paraffin-1
(Hep Par 1), cytokeratin (CK)18, and hepatocyte antigen,
but negative for CK7, CK20, placental alkaline phospha-
tase (PLAP), prostate-specific antigen (PSA), cancer
antigen 125 (CA125), epithelial membrane antigen
(EMA), cluster of differentiation (CD) 117, and CEA,
which confirmed that the seminal vesicle tumor was
metastatic HCC. In May 2009, a abdominal CT review-
ing revealed multiple metastatic foci in the abdominal
cavity in local hospital. Thus, the patient came to our
hospital again in order to receive further therapy by the
Table 1 Laboratory test results of blood routine examination, liver function and serous AFP at different time
Date WBC(10
9/l) RBC(10
12/l) HGB(g/l) PLT(10
9/l) ALT(u/l) AST(u/l) AFP(ng/ml)
06.09 4.80 3.85 103 84 30 42 3350
07.03 3.62 4.32 121 88 28 40 2249
07.09 5.03 4.55 139 82 32 38 897
08.09 4.71 4.40 135 135 135 78 772
09.01 4.43 3.44 103 125 14 20 3350
09.08 4.89 4.49 133 174 19 25 4689
Figure 1 US image shows that the echogenic dots thicken
slightly, and the echo strengthen slightly. A well-defined and
regular-appearance echo zone (2.7 cm × 2.3 cm) is found in the
right lobe of the liver. Moreover, A well-defined, and heterogeneous
hyperechoic mass (2.1 cm × 2.0 cm) is found in the right lobe
neighboring to the porta hepatis.
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lower abdomen by physical examination. Laboratory test
results included the following: white blood cell count,
4890/μl; red blood cell count, 4490 × 10
3/μl; hemoglo-
bin, 13.3 g/dl; platelets, 174 × 10
3/μl; aspartate amino-
transferase, 25 U/L; alanine aminotransferase, 19 U/L.
The level of serum AFP was elevated to 4689 ng/ml
(Table 1). Abdominal ultrasound examination revealed
that there was a dense echo zone in right anterior lobe
and right posterior lobe of the liver, respectively. More-
over, a low echo area with clear circumscription was
found at the ahead of head of pancreas. Thus, all these
foci were treated by microwaves. However, CT imaging
revealed multiple metastatic foci in the abdominal and
pelvic cavities in September 2009 (Figure 7). Of course,
the Written informed consent was obtained from the
patient for publication of this case report and any
accompanying images.
Discussion
Metastasis from the liver to extrahepatic tissues is not
common for HCC (13.5%-42% of cases) and has a poor
prognosis [4-6]. For unknown reasons, the seminal vesi-
cle is an extremely rare site of metastasis for HCC;
therefore, clinical data is limited.
Tumors of the seminal vesicles may be primary
tumors or secondary tumors originating from adjacent
organs such as the bladder, prostate, or rectum. Primary
seminal vesicle tumors are rare and may be benign
(papillary adenoma, cystadenoma, hydatid cyst, and
amyloid deposition) or malignant (adenocarcinoma, sar-
coma, cystosarcoma phyllodes, primary seminoma, and
carcinoid). Adenocarcinoma is the most frequent malig-
nant tumor. Therefore, we first excluded it before diag-
nosing the mass as metastasis from HCC. In 1956,
Dalgaard and Giertson [9] established the following cri-
teria for the diagnosis of primary seminal vesicle adeno-
carcinoma: 1) the tumor should be a microscopically
verified carcinoma, localized exclusively or mainly to the
seminal vesicle; 2) the presence of other simultaneous
primary carcinoma should be excluded; and 3) the
tumor should preferably resemble the architecture of
the non-neoplastic seminal vesicle.
Figure 2 US image shows that the echogenic dots are
intensive, dim, and mal-distributed. An ill-defined and irregular
dense echo zone (3.7 cm × 3.3 cm) is found in left lobe, and the
echogenic dots are confused and disorderly. Moreover, a dense
echo zone (1.8 cm × 1.7 cm) is found in right posterior lobe, and
the internal echo are well-distributed.
Figure 3 US image shows that the echogenic dots are
intensive, dim, and heterogeneous. Multiple dense echo zones
with inequality of size are found, and the larger (5.0 cm × 3.1 cm)
locats in the left lobe, and the internal echo is well-distributed
insufficiently.
Figure 4 (A, B) A microscopic view of the tumor in the seminal
vesicle: the tumor cells arranged in trabecular and solid, which
is compatible with the original HCC (C, D).
Figure 5 The tumor cells from the seminal vesicle (A, B) and
liver (C, D) were positive for GPC3.
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Moreover, according to the surgical doctor’si n t r o d u c -
tion, the mass was only found in seminal vesicle during
the operation. In addition, the histopathological charac-
teristics of the mass from seminal vesicle were similar to
that of primary HCC, although it had a poorly differen-
tiated appearance. Immunohistochemically, the tumor
cells were positive for GPC3, AFP, hepatocyte antigen,
HepPar1, and CK18, but negative for CK7, CK20, PLAP,
PSA, CA125, EMA, CD117, and CEA. Primary seminal
vesicle adenocarcinoma expresses these markers as well
as CK7, CA125 and CEA but not AFP, GPC3 and hepa-
tocyte antigen [10]. It is known to all, AFP is a relatively
specific but rather insensitive marker for hepatocellular
differentiation and is present in only one quarter of the
cases. Recently, GPC3 has been reported as novel serum
and histochemical marker for HCC, with positive stain-
ing in 72% to 100% of cases [11-16]. Thus, based on the
tumor cells positive reactivity for GPC3, AFP, hepato-
cyte antigen, Hep Par 1, and CK18, we thought that the
seminal vesicle mass should firstly be considered as a
metastatic HCC lesion. Of course, AFP, HepPar1 and
GPC3 were not only positive in HCC. Many malignant
tumors with AFP producing and hepatoid features
resembling HCC, such as hepatoid adenocarcinoma of
the stomach and primary hepatoid yolk sac tumor (H-
YST) of ovary and testis, especially the latter, express
AFP, Hep Par 1 and GPC3 [17,18]. Namely, AFP, Hep
Par 1 and GPC3 are useful markers for HCC, but not
entirely specific. However, the YST usually occurs in
younger patients, and most of them occur in the ovaries
and testis. About 20% arise in extraovarian sites, includ-
ing the mediastinum, sacrococcygeal region, cervix,
vulva, pelvis, and retroperitoneum [19-24]. We do not
believe primary H-YST of the seminal vesicle has been
reported in the literature. Moreover, gonadal dysgenesis
and the presence of a residual component of typical
yolk sac tumor or a polyvesicular vitelline pattern, or
glandular-like structure some with mucin production, is
helpful for differential diagnosis. In addition, immuno-
histochemically, the tumor cells of H-YSTs are positive
for CK besides AFP and HepPar1, and negative for
hepatocyte antigen, CK20, CEA and EMA. Thus, we
finally considered it was a metastatic HCC lesion based
on its clinical and pathological features.
No sufficient data is currently available regarding treat-
ment for HCC with metastasis to the seminal vesicle.
However, the prognosis appears to be poor. In our case,
the patient had undergone regular radiofrequency abla-
tion since the diagnosis of HCC, but intrahepatic and
seminal vesicle metastatic lesions were found after half a
year and 27 months, respectively. It was worse that CT
revealed multiple metastatic foci in the abdominal and
pelvic cavities after 32 months and 3 years, respectively.
In conclusion, the seminal vesicle is an extremely rare
metastatic site for HCC, and the prognosis is very poor.
Although AFP, Hep Par 1, hepatocyte antigen and
GPC3 are useful markers for HCC. They are not, how-
ever, entirely specific, showing different extent staining
in hepatoid adenocarcinoma and H-YST. Thus, a combi-
nation of clinical and pathological features is necessary
for a correct diagnosis, and primary tumor should be
excluded before diagnosing metastatic foci,
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